Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Journal of Statistical Physics
|
July 30, 2014
Bootstrapping on undirected binary networks via statistical mechanics
Hsieh Fushing, Chen Chen, Shan-Yu Liu, et al.
Plos One
|
June 15, 2018
From patterned response dependency to structured covariate dependency: Entropy based categorical-pattern-matching
Hsieh Fushing, Shan-Yu Liu, Yin-Chen Hsieh, et al.
Acta Crystallographica. Section E, Structure Reports Online
|
May 18, 2011
Cinnamyl 8-meth-oxy-2-oxo-2H-chromene-3-carboxyl-ate
Cui-Lian Xu, Shan-Yu Liu, Cai-Xia Wang, et al.
Acta Crystallographica. Section E, Structure Reports Online
|
May 18, 2011
Menthyl 2-oxo-2H-chromene-3-carboxyl-ate
Cui-Lian Xu, Shan-Yu Liu, Gang Chen, et al.
Statistical Methods in Medical Research
|
May 31, 2019
Propensity score analysis for correlated subgroup effects
Shan-Yu Liu, Chunyan Liu, Eddie Nehus, et al.
AIDS and Behavior
|
March 10, 2025
Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV
Moti Ramgopal, Dylan J Mezzio, Keith Dunn, et al.
Molecular Cytogenetics
|
August 23, 2025
Potential role of SLC6A3 in neurodevelopmental impairments associated with corpus callosum abnormalities: insights from CNV analysis and clinical phenotyping
Shan-Yu Liu, Wei Huang, Hui-Lin Ou, et al.
The Lancet. HIV
|
December 24, 2022
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Samir K Gupta, Mezgebe Berhe, Gordon Crofoot, et al.
AIDS (London, England)
|
October 7, 2025
Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized study
Debbie Hagins, Mezgebe Berhe, Gordon E Crofoot, et al.
Annals of Internal Medicine
|
December 22, 2025
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study
Amy E Colson, Gordon E Crofoot, Peter J Ruane, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Journal of Statistical Physics
|
July 30, 2014
Bootstrapping on undirected binary networks via statistical mechanics
Hsieh Fushing, Chen Chen, Shan-Yu Liu, et al.
Plos One
|
June 15, 2018
From patterned response dependency to structured covariate dependency: Entropy based categorical-pattern-matching
Hsieh Fushing, Shan-Yu Liu, Yin-Chen Hsieh, et al.
Acta Crystallographica. Section E, Structure Reports Online
|
May 18, 2011
Cinnamyl 8-meth-oxy-2-oxo-2H-chromene-3-carboxyl-ate
Cui-Lian Xu, Shan-Yu Liu, Cai-Xia Wang, et al.
Acta Crystallographica. Section E, Structure Reports Online
|
May 18, 2011
Menthyl 2-oxo-2H-chromene-3-carboxyl-ate
Cui-Lian Xu, Shan-Yu Liu, Gang Chen, et al.
Statistical Methods in Medical Research
|
May 31, 2019
Propensity score analysis for correlated subgroup effects
Shan-Yu Liu, Chunyan Liu, Eddie Nehus, et al.
AIDS and Behavior
|
March 10, 2025
Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV
Moti Ramgopal, Dylan J Mezzio, Keith Dunn, et al.
Molecular Cytogenetics
|
August 23, 2025
Potential role of SLC6A3 in neurodevelopmental impairments associated with corpus callosum abnormalities: insights from CNV analysis and clinical phenotyping
Shan-Yu Liu, Wei Huang, Hui-Lin Ou, et al.
The Lancet. HIV
|
December 24, 2022
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Samir K Gupta, Mezgebe Berhe, Gordon Crofoot, et al.
AIDS (London, England)
|
October 7, 2025
Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized study
Debbie Hagins, Mezgebe Berhe, Gordon E Crofoot, et al.
Annals of Internal Medicine
|
December 22, 2025
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study
Amy E Colson, Gordon E Crofoot, Peter J Ruane, et al.
Page
of 1